1.
Eur J Clin Microbiol Infect Dis
; 43(7): 1475-1480, 2024 Jul.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38753112
RESUMEN
Implant-related infections may need suppressive antibiotic therapy (SAT). We describe a SAT strategy using dalbavancin with therapeutic drug monitoring (TDM). This is a retrospective bicentric study of patients with implant-related infection who received dalbavancin SAT between January 2021 and September 2023. Fifteen patients were included. Median number of injections was 4 (IQR: 2-7). Median time between two reinjections was 57 days (IQR 28-82). Dalbavancin plasma concentrations were above 4 mg/L for 97.9% of dosages (93/95) and above 8 mg/L for 85% (81/95). These results support the use of dalbavancin SAT for implant-related infections.
Asunto(s)
Antibacterianos , Monitoreo de Drogas , Infecciones Relacionadas con Prótesis , Teicoplanina , Humanos , Teicoplanina/análogos & derivados , Teicoplanina/uso terapéutico , Teicoplanina/administración & dosificación , Antibacterianos/uso terapéutico , Antibacterianos/farmacocinética , Antibacterianos/administración & dosificación , Estudios Retrospectivos , Masculino , Anciano , Femenino , Persona de Mediana Edad , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Anciano de 80 o más Años
2.
3.
Therapie
; 76(5): 488-490, 2021.
Artículo
en Francés
| MEDLINE
| ID: mdl-32723578